Literature DB >> 3116733

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.

J M Dickinson1, D A Mitchison.   

Abstract

In a comparison of in vitro properties of rifapentine (RIF) and rifampicin (RMP), the minimal inhibitory concentration of RIF against Mycobacterium tuberculosis in Tween-albumin liquid medium was usually 0.02 micrograms/ml, 2-3 times lower than for RMP; the bactericidal activity against a log phase culture was slightly less than that of RMP and the recovery after pulsed exposures to 1 microgram/ml of RIF or RMP lasting 6, 24 and 96 h was identical for the two rifamycins. These findings are used to interpret published data from the chronic experimental murine tuberculosis model and support the view that in the mouse, the efficacy of RIF in widely spaced intermittent chemotherapy is the result of its long half-life.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116733     DOI: 10.1016/0041-3879(87)90026-2

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  15 in total

1.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

Authors:  L Heifets; T Sanchez; J Vanderkolk; V Pham
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 5.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

6.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

8.  Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Authors:  N Veziris; N Lounis; A Chauffour; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

9.  Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.

Authors:  N Mor; B Simon; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 10.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.